


Product Name : BI 1015550
Cat. No. : PC-49676
CAS No. : 1423719-30-5
Molecular Formula : C₂₀H₂₅ClN₆O₂S
Molecular Weight : 448.97
Target : Phosphodiesterase (PDE)
Solubility : 10 mM in DMSO



Biological Activity

BI 1015550 (Nerandomilast, VRN024219) is a potent, selective **PDE4B** inhibitor that preferentially inhibits hydrolysis of cAMP by PDE4B with IC₅₀ of 10 nM, weakly inhibits PDE4A/4C/4D (IC₅₀=248/8700/91 nM, respectively).

BI 1015550 displays no significant activity against human PDE7A and human PDE3A, and PDE1C, PDE9A, human PDE2A and PDE5 at 10 μM.

BI 1015550 inhibited LPS-induced TNF-α release with an IC₅₀ 35 nM in human PBMCs, inhibited phytohemagglutinin P-induced IL-2 release with IC₅₀ of 9 nM.

BI 1015550 completely inhibited LPS-stimulated TNF-α release with an IC₅₀ in rat whole blood, inhibited TNF-α release up to 70–80% with an IC₅₀ of 670 nM human whole blood.

BI 1015550 (0.01, 0.1, and 1 mg/kg, p.o.) inhibited LPS-stimulated TNF-α release in whole blood ex vivo in mice with ED₅₀ of 0.04 mg/kg.

BI 1015550 (0.01, 0.1, and 1 mg/kg, p.o.) inhibited LPS-induced lung neutrophil influx in male Wistar rats with an ED₅₀ of 0.1 mg/kg.

BI 1015550 inhibited α-SMA protein expression of TGF-β-stimulated IPF-LF with an IC₅₀ of 210 nM, showed a synergistic effect in combination with Nintedanib on fibroblast proliferation.

BI 1015550 is a promising oral clinical candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibro-proliferative diseases.

References

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com